Search research articles
Contact Us
Filters
Showing results (71-80 of 121) with videos related to
Page
of 13
Sort By:
The Lancet. Oncology
|
April 3, 2023
Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study
Toni K Choueiri, David F McDermott, Jaime Merchan, et al.
The Oncologist
|
August 11, 2019
Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial
Daniel J George, Colin Hessel, Susan Halabi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 5, 2013
A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases
Richard J Lee, Philip J Saylor, M Dror Michaelson, et al.
Nature Medicine
|
April 23, 2021
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
Toni K Choueiri, Todd M Bauer, Kyriakos P Papadopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2017
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
Toni K Choueiri, Susan Halabi, Ben L Sanford, et al.
Clinical Genitourinary Cancer
|
May 9, 2014
Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer
Guru Sonpavde, Gregory R Pond, Andrew J Armstrong, et al.
Clinical Genitourinary Cancer
|
April 3, 2016
Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma
Kathleen M Mahoney, Susanna Jacobus, Rupal S Bhatt, et al.
The Oncologist
|
September 8, 2018
An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma
Toni K Choueiri, M Dror Michaelson, Edwin M Posadas, et al.
The New England Journal of Medicine
|
January 12, 2007
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J Motzer, Thomas E Hutson, Piotr Tomczak, et al.
The Oncologist
|
June 8, 2019
A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors
M Dror Michaelson, Shilpa Gupta, Neeraj Agarwal, et al.
Page
of 13
Search research articles
Search
Showing results (71-80 of 121) with videos related to
Sort By:
Page
of 13
The Lancet. Oncology
|
April 3, 2023
Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study
Toni K Choueiri, David F McDermott, Jaime Merchan, et al.
The Oncologist
|
August 11, 2019
Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial
Daniel J George, Colin Hessel, Susan Halabi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 5, 2013
A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases
Richard J Lee, Philip J Saylor, M Dror Michaelson, et al.
Nature Medicine
|
April 23, 2021
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
Toni K Choueiri, Todd M Bauer, Kyriakos P Papadopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2017
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
Toni K Choueiri, Susan Halabi, Ben L Sanford, et al.
Clinical Genitourinary Cancer
|
May 9, 2014
Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer
Guru Sonpavde, Gregory R Pond, Andrew J Armstrong, et al.
Clinical Genitourinary Cancer
|
April 3, 2016
Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma
Kathleen M Mahoney, Susanna Jacobus, Rupal S Bhatt, et al.
The Oncologist
|
September 8, 2018
An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma
Toni K Choueiri, M Dror Michaelson, Edwin M Posadas, et al.
The New England Journal of Medicine
|
January 12, 2007
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J Motzer, Thomas E Hutson, Piotr Tomczak, et al.
The Oncologist
|
June 8, 2019
A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors
M Dror Michaelson, Shilpa Gupta, Neeraj Agarwal, et al.
Page
of 13